Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XR 311

Drug Profile

XR 311

Alternative Names: HN 66000; KSB 311M; KSB 311N; KSB 311P; KSB 311R; PEP04; Project KSB311R; SOT-107; TF CRM 107; Transferrin-CRM 107; TransMID; TransMID 107M; TransMID 107N; TransMID 107P; TransMID 107R

Latest Information Update: 03 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare; National Institutes of Health (USA)
  • Developer Nycomed; Sosei; Xenova Group
  • Class Antineoplastics; Drug conjugates; Immunotoxins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; CNS cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS cancer; Glioblastoma; Glioma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Apr 2005 Xenova has licensed XR 311 to PharmaEngine in the Republic of China and in the Republic of South Korea
  • 14 Feb 2005 XR 311 has received orphan drug status for glioma in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top